Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 200
- Avg volume
- —
- Day's range
- $0.35 – $0.35
- Shares out
- —
- Stochastic %K
- —
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury. The company is headquartered in Fitzroy, Australia.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 1300 813 321
- Website
- https://dimerix.com
- Address
- 425 Smith Street, Fitzroy, Australia
Latest news
No headlines yet.
